Search: 
You do not have permission to access this chart.
Please Sign Up or Login
News for Akari Therapeutics, Plc (AKTX)
Newly released Crypto mining rig for Akari Therapeutics, Plc coins
minutes ago | Banggood.com
Everything Crypto on sale now!
58 minutes ago | Aliexpress.com
Akari Therapeutics Announces Private Placement
a month ago | GlobeNewsWire
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
a month ago | GlobeNewsWire
Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder
3 months ago | Benzinga
AKTX Stock: Over 20% Increase Pre-Market Explanation
3 months ago | Pulse2
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
3 months ago | GlobeNewsWire
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
3 months ago | GlobeNewsWire
Akari Therapeutics' To Go With Pivotal Bullous Pemphigoid Study With Nomacopan
4 months ago | Benzinga
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
4 months ago | GlobeNewsWire
Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma
5 months ago | GlobeNewsWire
Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies
5 months ago | Benzinga

About:

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

10

Address:

Akari Therapeutics, Plc 75/76 Wimpole Street London W1G 9RT United Kingdom

Website:

http://www.akaritx.com

Phone:

44 20 8004 0270

Leave a comment

Your email address will not be published. Required fields are marked *